Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Novel synthetic diazonamide A analogue shows promise in preclinical studies

Feb. 26, 2007

Peregrine licensee begins phase I trial with TNT cancer agent

Feb. 26, 2007

New phase I trial studies L-annamycin in pediatric ALL and AML

Feb. 26, 2007

Pharmacyclics receives refusal to file letter for Xcytrin

Feb. 23, 2007

Hybrigenics focuses research on USP inhibitors for cancer

Feb. 23, 2007

GPC Biotech launches satraplatin expanded access program

Feb. 23, 2007

Identification of active sites of Polo-like kinases useful for developing new cancer therapies

Feb. 23, 2007

Recent patents cover new therapeutic agents for cancer

Feb. 23, 2007

Vascular disruption agent BNC-105 begins safety studies in animals

Feb. 22, 2007

Disruption of the CXCR4-CXCL12 and VLA4-VCAM-1 axes may sensitize leukemia cells to chemotherapy

Feb. 22, 2007

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...